These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37356358)

  • 21. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
    Garrido P; de Castro J; Concha Á; Felip E; Isla D; López-Ríos F; Paz-Ares L; Ramírez J; Sanz J; Gómez JJ
    Clin Transl Oncol; 2012 May; 14(5):338-49. PubMed ID: 22551539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Enguita AB
    Clin Transl Oncol; 2023 May; 25(5):1252-1267. PubMed ID: 36571695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.
    Felip E; Gridelli C; Baas P; Rosell R; Stahel R;
    Ann Oncol; 2011 Jul; 22(7):1507-1519. PubMed ID: 21536661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rate of
    Cheema PK; Raphael S; El-Maraghi R; Li J; McClure R; Zibdawi L; Chan A; Victor JC; Dolley A; Dziarmaga A
    Curr Oncol; 2017 Feb; 24(1):16-22. PubMed ID: 28270720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
    Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
    J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.
    Ionescu DN; Stockley TL; Banerji S; Couture C; Mather CA; Xu Z; Blais N; Cheema PK; Chu QS; Melosky B; Leighl NB
    Curr Oncol; 2022 Jul; 29(7):4981-4997. PubMed ID: 35877256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updates in pathology and molecular diagnostics to inform the evolving landscape of thoracic surgery and oncology.
    Naso J; Lo YC; Sholl LM
    J Surg Oncol; 2023 Feb; 127(2):244-257. PubMed ID: 36630101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
    Sholl LM; Aisner DL; Allen TC; Beasley MB; Borczuk AC; Cagle PT; Capelozzi V; Dacic S; Hariri L; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao MS; Yatabe Y;
    Arch Pathol Lab Med; 2016 Apr; 140(4):341-4. PubMed ID: 26780537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chinese expert consensus on refractory lung cancer].
    Chinese Thoracic Society
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):301-312. PubMed ID: 38599804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
    Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
    Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expert Consensus on Adjuvant Therapy of Non-small Cell Lung Cancer from China Thoracic Surgeons (2018 Version)].
    Thoracic Surgery Committee on Adjuvant Therapy of Non-small Cell Lung Cancer
    Zhongguo Fei Ai Za Zhi; 2018 Oct; 21(10):731-737. PubMed ID: 30309423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia.
    Mitsudomi T; Tan D; Yang JC; Ahn MJ; Batra U; Cho BC; Cornelio G; Lim T; Mok T; Prabhash K; Reungwetwattana T; Ren SX; Singh N; Toyooka S; Wu YL; Yang PC; Yatabe Y
    J Thorac Oncol; 2023 Apr; 18(4):436-446. PubMed ID: 36379356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Belén Enguita A
    Rev Esp Patol; 2023; 56(2):97-112. PubMed ID: 37061248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    Felip E; Concha Á; de Castro J; Gómez-Román J; Garrido P; Ramírez J; Isla D; Sanz J; Paz-Ares L; López-Ríos F
    Clin Transl Oncol; 2015 Feb; 17(2):103-12. PubMed ID: 25351175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
    Kim ES; Roy UB; Ersek JL; King J; Smith RA; Martin N; Martins R; Moore A; Silvestri GA; Jett J
    J Thorac Oncol; 2019 Mar; 14(3):338-342. PubMed ID: 30709747
    [No Abstract]   [Full Text] [Related]  

  • 36. Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre.
    Potter AJ; Colebatch AJ; Rawson RV; Ferguson PM; Cooper WA; Gupta R; O'Toole S; Saw RPM; Ch'ng S; Menzies AM; Long GV; Scolyer RA
    Pathology; 2022 Aug; 54(5):526-532. PubMed ID: 35249747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach.
    Salto-Tellez M; Tsao MS; Shih JY; Thongprasert S; Lu S; Chang GC; Au JS; Chou TY; Lee JS; Shi YK; Radzi A; Kang JH; Kim SW; Tan SY; Yang JC
    J Thorac Oncol; 2011 Oct; 6(10):1663-9. PubMed ID: 21869714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases.
    Ponce S; Bruna J; Juan O; López R; Navarro A; Ortega AL; Puente J; Verger E; Bartolomé A; Nadal E
    Crit Rev Oncol Hematol; 2019 Jun; 138():190-206. PubMed ID: 31092376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of proteomics in non-small-cell lung cancer.
    Cho WC
    Expert Rev Proteomics; 2016; 13(1):1-4. PubMed ID: 26577456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.